Letrozol SUN 2,5 mg

Description

Pharmacology

The pharmacological action is antitumour.

Indications

Disseminated breast cancer, mainly in postmenopausal women, including resistance to treatment with anti-estrogens.

Contraindications

Hypersensitivity, premenopausal period, marked renal impairment (creatinine Cl < 10 ml/min), pregnancy, breastfeeding (discontinue).

Undesirable effects

Headache, dizziness, general weakness, nausea, vomiting, changes in appetite (more often decreased), constipation, peripheral oedema, flushing, myalgia, skin rashes, weight changes, hair thinning, gynaecological bleeding, oozing bloody vaginal discharge, skin rashes.

Method of use and dosage

Intravenously, 2.5 mg once daily daily, long course (5-10 years and over).
Precautions: It is desirable to test estrogen receptor status before starting treatment. The appropriateness of prescribing to patients without lymph node involvement is determined on an individual basis: the degree of malignancy, tumour size, presence of oestrogen receptors, age are taken into account. During the treatment period, it is not advisable to drive a car or perform other activities requiring increased attention and speed of reaction.